Post-earnings recap
Reported
Mon, May 11, 2026
EPS actual
$0.79
EPS est.
$0.58
EPS surprise
+36.21%
1-day move
+0.00%
Catalyst Pharmaceuticals reported a strong earnings per share that exceeded expectations, which is a positive indicator for the company's profitability. However, the lack of revenue data and guidance leaves some uncertainty about future performance. The stock reaction remained unchanged at 0.0%, indicating that investors may be waiting for more information before making decisions.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.79 | $0.64 | +36.21% |
| Revenue | — | $147M | — |
No transcript is on record, and the analysis is based solely on numerical results.
Catalyst Pharmaceuticals, Inc. (CPRX) is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases. With a market cap of $4 billion, it plays a crucial role in the healthcare sector, particularly in addressing unmet medical needs for patients with serious conditions.
Last quarter
In Q4-2025, Catalyst Pharmaceuticals reported an EPS of $0.68, significantly exceeding analyst expectations. The stock reacted positively, gaining 2.77% the following day.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+36.69%
Avg 1-day reaction
+0.67%
Analysts expect Catalyst Pharmaceuticals to maintain its strong performance with a consensus EPS of $0.64 and revenue of $147 million for Q1-2026. The company has consistently beaten earnings expectations in the past.
Bull case
If the company exceeds EPS estimates, it could signal strong demand for its products and further validate its growth strategy, potentially boosting investor confidence.
Bear case
Conversely, if earnings fall short of expectations, it may raise concerns about the sustainability of its growth and lead to a negative market reaction.
Key metrics to watch
EPS
$0.64Earnings per share is a key indicator of profitability and helps assess the company's financial health.
Revenue
$147MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the EPS exceed the consensus estimate of $0.64?
A beat on EPS would reinforce the company's growth trajectory and could lead to a positive stock reaction.
Q2
What are the revenue expectations for the quarter, particularly in relation to the $147 million consensus?
Revenue performance is critical for assessing the company's market position and growth potential, influencing investor sentiment.
—
Est. EPS
$0.97
Est. Rev
$693M
Impl. Move
±7.6%
Why consensus could be wrong
The consensus may underestimate the company's ability to leverage its recent product launches, which could drive higher-than-expected revenue growth this quarter.
Supporting evidence
Catalyst has consistently beaten EPS estimates, suggesting strong operational execution.
The options market is pricing in a larger move than historical averages, indicating potential for a significant reaction.
Recent product developments may not be fully reflected in analyst forecasts.
Key risk
If revenue comes in above $154 million, it could challenge the current consensus and shift market sentiment.
Pre-commit to what would confirm each case.
The market is debating the sustainability of Catalyst's growth, with recent earnings history showing a consistent ability to beat estimates.
Bull confirmed if
An EPS of $0.66 or higher would confirm the bull case and indicate strong operational performance.
Bear confirmed if
An EPS below $0.62 would raise concerns about the company's growth prospects and confirm the bear case.
What the market is pricing for the move.
Implied Move
±4.1%
Historical Avg
±1.4%
The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings announcement.
Options are pricing ±3.9% while CPRX has averaged ±1.4% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
39.8%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 6 of 16 (38%)
This setup has occurred 30 times across Health Care in the last 2 years. 10 of 16 (63%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.2% (modestly positive historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Catalyst beats expectations, history suggests the stock could rise by about 0.32% the following day, confirming strong demand for its products.
In line / cautious
If the results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss could lead to a decline, with historical data suggesting an average drop of around 1.94% if earnings do not meet expectations.
The lines on the call that would change the story.